                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, DC 20549


                                ---------------

                                    FORM 8-K

                                 CURRENT REPORT


                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


                Date of Report (Date of earliest event reported):
                                February 6, 2003


                           CORNICHE GROUP INCORPORATED
           -----------------------------------------------------------
               (Exact name of registrant as specified in charter)


  Delaware                       0-10909                     22-2343568
- -------------------         -----------------          ---------------------
(State or other              (Commission File             (IRS Employer
jurisdiction of                Number)                    Identification No.)
incorporation)


 610 SOUTH INDUSTRIAL BOULEVARD, SUITE 220, EULESS, TEXAS      76040
- --------------------------------------------------------------------------------
       (Address of principal executive offices)              (Zip Code)


                                  864-963-8718
                     --------------------------------------
                          Registrant's Telephone Number


<PAGE>

ITEM 5.   OTHER EVENTS AND REGULATION FD DISCLOSURE

          Corniche Group Incorporated (the "Company") has appointed Mark Weinreb
as a member of the Board of Directors and as its  President and Chief  Executive
Officer.  The Company and Mr. Weinreb have been exploring business plans for the
Company that may involve, under the name "Phase III Medical, Inc.", entering the
medical  sector by acquiring  or  participating  in one or more  biotech  and/or
medical  companies or technologies,  owning one or more drugs or medical devices
that may or may not yet be available to the public,  or acquiring  rights to one
or more of such drugs or medical devices or the royalty streams  therefrom.  Mr.
Weinreb has been  appointed to finalize and execute the  Company's  new business
plan.  In any  event,  the  Company  will need to recruit  management,  business
development   and  technical   personnel,   and  develop  its  business   model.
Accordingly,  it will be necessary  for the Company to raise new capital.  There
can be no assurance that any such business plan developed by the Company will be
successful, that the Company will be able to acquire such new business or rights
or raise new capital,  or that the terms of any transaction will be favorable to
the Company.

          Mr.  Weinreb,  age 49,  has many  years  of  experience  with  medical
services,  equipment and operations,  as well as with development  stage private
and public  companies.  From 2000 until 2002,  Mr. Weinreb  served as the  Chief
Executive Officer of Jestertek, Inc., a 12-year old software development company
pioneering gesture recognition and control using proprietary  inter-active video
technology.  He was recruited to commercialize Jestertek's technology (initially
focused on interactive entertainment), find the necessary financing for on-going
development,  and  position  the company for an eventual  IPO.  Recognizing  the
market  potential in  the  rehabilitation  medicine  field,  Mr. Weinreb  helped
develop  the first of its  kind  interactive  "marker less" and  peripheral-free
computer controlled,  physical therapy and exercise systems, using the company's
proprietary  video  gesture  control  technology.  Prior  to  his  service  with
Jestertek,  Inc.,  Mr.  Weinreb  was the  founder of Big City  Bagels,  Inc.,  a
national chain of franchised upscale bagel bakeries,  which went public in 1995.
Mr.  Weinreb was Big City Bagels'  Chief  Executive  Officer  until 1999 when he
redirected  its business  focus and completed a merger with an internet  service
provider.  In 1976, Mr. Weinreb joined Bio Health Laboratories,  Inc., a medical
diagnostic  laboratory  providing  clinical  testing  services  for  physicians,
hospitals  and  other  medical   laboratories.   He  became  an  owner  and  the
laboratory's  Chief Operating Officer from 1982 to 1989.  Mr. Weinreb received a
Bachelor of Arts  degree in 1975 from  Northwestern  University  and a Master of
Science  degree  in 1982  in  Medical  Biology,  from  C.W.  Post,  Long  Island
University.

          To secure Mr.  Weinreb's  service  as  President  and Chief  Executive
Officer,  the Company has entered into an employment agreement with Mr. Weinreb.
The  employment  agreement  has an initial term of three years,  with  automatic
annual  extensions  unless  terminated by the Company or Mr. Weinreb at least 90
days prior to  applicable  anniversary  date.  The Company has agreed to pay Mr.
Weinreb an annual salary of $180,000 for the initial year of the term,  $198,000
for the second year of the term, and $217,800 for the third year of the term. In
addition,  he is  entitled  to an annual  bonus in the amount of $20,000 for the
initial year in the event,  and  concurrently  on the date, that the Company has
received  debt  and/or  equity  financing  in the  aggregate  amount of at least
$1,000,000  since the beginning of his service,  and $20,000 for each subsequent
year of the term, without condition.


<PAGE>

          In addition,  the Company,  pursuant to its newly  adopted 2003 Equity
Participation  Plan, entered into a Stock Option Agreement with Mr. Weinreb (the
"Initial Option  Agreement").  Under the Initial Option  Agreement,  the Company
granted Mr. Weinreb the right and option,  exercisable for 10 years, to purchase
up to 2,500,000  shares of the  Company's  common stock at an exercise  price of
$0.03 per share and  otherwise  upon the terms set forth in the  Initial  Option
Agreement.  In addition,  in the event that the closing  price of the  Company's
common  stock  equals or  exceeds  $0.50 per share for any five (5)  consecutive
trading days during the term of the employment agreement (whether during initial
term or an annual extension), the Company has agreed to grant to Mr. Weinreb, on
the day immediately  following the end of the five (5) day period, an option for
the purchase of an additional 2,500,000 shares of the Company's common stock for
an exercise price of $0.50 per share,  pursuant to the 2003 Equity Participation
Plan and a Stock Option Agreement to be entered into between the Company and Mr.
Weinreb containing substantially the same terms as the Initial Option Agreement,
except  for the  exercise  price  and that the  option  would be  treated  as an
"incentive  stock option" for tax purposes only to the maximum extent  permitted
by law (the "Additional Option Agreement").  Mr. Weinreb has agreed that he will
not resell  publicly  any shares of the  Company's  common stock  obtained  upon
exercise of any Initial  Agreement or the Additional  Option  Agreement prior to
the first anniversary of the date of the employment agreement.

          In  connection  with  the  hiring  of Mr. Weinreb  and  the  Company's
anticipated  new  business  line,  the  Company  intends  to call a  meeting  of
stockholders:  (1) to elect five  directors  (including  Mr. Weinreb and, if  he
requests,  a person  designated by him); (2) to ratify the Company's 2003 Equity
Participation  Plan pursuant to which 15,000,000  shares of the Company's common
stock are authorized to be issued;  (3) to approve an amendment to the Company's
Certificate  of  Incorporation  to increase the  authorized  number of shares of
common stock to  250,000,000;  and (4) to approve a change of the Company's name
to "Phase III Medical, Inc."

                                    * * * * *


This Report contains forward-looking statements made pursuant to the safe harbor
provisions   of  the  Private   Securities   Litigation   Reform  Act  of  1995.
Forward-looking  statements  represent  management's  judgment  regarding future
events.  Although  management  believes that the expectations  reflected in such
statements are reasonable,  they give no assurance that such  expectations  will
prove to be correct and you should be aware that  actual  results  could  differ
materially  from those  contained  in the  forward-looking  statements  due to a
number of factors.  These  factors  include  the risk that the  Company  will be
unable to raise capital,  to enter successfully the biotech or medical business,
to have appropriate personnel, or the risks inherent in any new business venture
or those  detailed in the Company's  other reports filed with the Securities and
Exchange  Commission.  The Company  undertakes no obligation to update or revise
the information contained in this Report whether as a result of new information,
future events or circumstances or otherwise.



<PAGE>

ITEM 7.   FINANCIAL STATEMENTS AND EXHIBITS

          Exhibit 99.1  Press Release

          Exhibit 99.2  Employment Agreement dated as of February 6, 2003 by and
                        between Corniche Group Incorporated and Mark Weinreb

          Exhibit 99.3  Stock  Option Agreement  dated  as  of  February 6, 2003
                        between Corniche Group Incorporated and Mark Weinreb

          Exhibit 99.4  Corniche Group  Incorporated 2003  Equity  Participation
                        Plan


<PAGE>


                                   SIGNATURE


          Pursuant to the  requirements of the Securities  Exchange Act of 1934,
the  registrant  has duly  caused  this report to be signed on its behalf by the
undersigned hereunto duly authorized.



                                           CORNICHE GROUP INCORPORATED


                                         By: /s/ James J. Fyfe
                                            ------------------------------------
                                             Name:  James J. Fyfe
                                             Title: Director


Dated:  February 11, 2003


